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Background: EGFR gene tyrosine kinase (TK) domain mutations in-
crease sensitivity of the receptor both for the effects of ligand and small 
molecule tyrosine kinase inhibitors (TKI). Retrospective and limited 
prospective data have indicated impressive activity (response rate and 
response duration) in patients with advanced EGFR mutant lung cancer. 
The FIELT study is a single arm multicenter phase II study evaluating 
the safety and efﬁcacy of ﬁrst-line erlotinib in patients with advanced 
NSCLC with a documented EGFR mutation. 
Patients and Methods: Because of the anticipated low prevalence of 
EGFR mutations in Caucasian populations and the consequent large 
recruitment base needed, 24 clinical centers in Belgium and Luxem-
burg are cooperating in the trial. Patients are pre-selected on pheno-
type: adenocarcinoma with no or little smoking history. Diagnostic 
formalin-ﬁxed biopsy samples are analysed centrally for quality and 
proportion of tumor cells. Samples with > 25% tumor cells of any size 
are examined by DGGE and sequencing of exons 18-24 of the EGFR 
gene. In addition EGFR IHC and FISH are performed. Patients with a 
TK domain mutation in their tumor are then prospectively treated with 
erlotinib (150mg/day) until progression. The primary endpoint of the 
study is PFS at 3 months (hypothesis > 70%). Secondary endpoints are 
RECIST and early metabolic response, feasibility of this set-up and 
duration of response and survival. 
Results: Thus far, 36 patients have been screened for the presence of 
EGFR mutations. Nine patients had inconclusive mutation analysis 
(insufﬁcient tissue quality). An EGFR mutation was found in 9 (25%, 
34% of evaluable) cases, L858 (2cases) and del E746-A750 (7 cases) 
and 6 of these patients have initiated ﬁrst-line erlotinib treatment. All 
mutations were found in never-smokers.
Results of the mutation analysis were returned to the participating 
investigator within 2 weeks. IHC was positive in 26/31(84%) of cases 
and 10/30 (33%) had increased gene copy number. 
There was no association between EGFR copy number and mutation 
status.
Responses and response duration: 3 PR (12+w, 12+w, 9+w); 1SD 
(36+w). Two early progressions (both exon 19 deletions) occurred at 6 
w and 12 w. One patient subsequently responded dramatically to one 
cycle of platinum-based chemo, but expired due to massive haemopty-
sis. In this patient a novel additional (possible resistance) mutation was 
found in exon 21.
Conclusions: Pre-selection of NSCLC patients on phenotypic basis 
leads to a satisfactory mutation detection rate in EGFR. It is feasible 
to perform a mutation analysis before selecting ﬁrst-line treatment in a 
multicenter context, although diagnostic tissue samples are insufﬁcient 
in 25% of cases.
P3-080 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Erlotinib as single agent in men with advanced or metastatic 
NSCLC: A retrospective analysis
Domine, Manuel1 Gurpide, Luis Alfonso2 Rosillo, Fernando3 Puertas, 
Javier4 Provencio, Mariano5 Rolfo, Christian6 Mendez, Miguel7 Lopez-
Brea, Marta8 Amador, Maria Luz9 Paz Ares, Luis10 
1 Fundacion Jimenez Diaz, Madrid, Spain 2 Clínica Universitaria de 
Navarra, Pamplona, Spain 3 Hospital Torrecardenas, Almeria, Spain 
4 Hospital del Rio Hortega, Valladolid, Spain 5 Hospital Universitario 
Puerta de Hierro, Madrid, Spain 6 Clinica Rotger, Palma de Mal-
lorca, Spain 7 Hospital General de Mostoles, Madrid, Spain 8 Hospital 
Universitario Marques de Valdecilla, Santander, Spain 9 Roche Farma, 
Madrid, Spain 10 Hospital Universitario 12 de Octubre, Madrid, Spain 
Background: Erlotinib is the ﬁrst and only HER-1/EGFR tyrosine-
kinase inhibitor (TKI) that has shown survival beneﬁt in a ranzomized, 
placebo controlled trial. Although an exploratory analysis demonstrated 
that the clinical beneﬁt of Erlotinib in survival was observed across 
most patient subgroups, responses were more common in certain pa-
tients such as women, never smokers, or patients with adenocarcinoma 
histology. The purpose of the analysis we present here was to describe 
outcome in terms of response and survival in the group of men with 
NSCLC treated with Erlotinib in a phase II clinical trial.
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Pts. with histologically conﬁrmed stage IIIB or IV NSCLC who had 
received treatment with chemotherapy in second or third line as well 
as chemotherapy-naïve patients non suitable for ﬁrst line conventional 
chemotherapy were eligible. Eligibility criteria were: ≥18 years old, 
ECOG 0-2, adequate bone marrow, hepatic and renal function and 
written informed consent. Male patients receiving Erlotinib 150 mg/day 
p.o until disease progression or withdrawal were the subject of this 
analysis. 
Results: From April 2004 to March 2006, 1.796 pts were included 
in the TargeT trial, of those 1.108 male pts. were evaluated for this 
analysis. 96% of pts were active or former smokers; median age: 66 y 
(range 28-95); histology: 43% adenocarcinoma (including BAC), 32% 
squamous; 18% large cell carcinoma; 6% other; 81% exhibited stage 
IV carcinoma. ECOG PS 0/1/2 (%) 20/55/26. The % of pts receiving 
Erlotinib in 1st/2nd/3rd or further lines were: 24/39/37.
Among 606 patients with evaluable disease, overall response rate of 
11.1%, with 42.2% of stabilization of disease (control disease rate: 
54.3%) was reached. Response rate to Erlotinib was higher among 
patients with adenocarcinoma when compared with other histologies 
and those without smoking habit, although nonsmokers comprised only 
4% of the sample. No statistically signiﬁcant differences were found in 
these subgroups in terms of control disease rate (higher than 50% in all 
cases).
Median time to progression was 3.5 months (95% CI: 3.1-3.8). Both in 
the univariate and multivariate analysis, absence of smoking habit (7.0 
vs. 3.3 months) and performance status 0-1 (3.6 vs. 2.8 month) were 
associated with longer time to progression. No differences in TTP be-
tween adenocarcinoma and squamous histology were detected (hazard 
ratio: 0.86; 95% IC: 0.79-1.05). 
Median overall survival was 5.1 months (95% CI: 4.6-5.8). In the Cox 
regression analysis, performance status (0-1) was the only factor as-
sociated with longer survival (p<0.001). 
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Skin rash (62.2%), asthenia (34.1%) and diarrhoea (30.1%) were the 
most frequent toxicities. 
Conclusions: This subgroup analysis conﬁrms the activity of Erlotinib 
in male patients with advanced NSCLC. Survival beneﬁt was also evi-
dent and no differences between subgroups were observed (with the ex-
ception of performance status). This retrospective analysis, along with 
the subgroup analyses of the BR.21 study, suggests that at this moment, 
gender should not be a criterion to decide treatment with Erlotinib.
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Background: Poor performance status is one of the prognostic factors 
in patient with lung cancer; this group constitutes between 30%-40% 
of the patients with advanced non small cell lung cancer (NSCLC) and 
has a low life expectancy. Erlotinib, an oral inhibitor of the Epidermal 
Grow Factor (EGFR) have demonstrated to improve survival, prolong 
disease progression, and delay worsening of cancer-related symptoms, 
with a mild safety proﬁle, which make Erlotinib an ideal candidate to 
treat those patients with poor performance status (PS). Here we present 
results of an analysis of a large subgroup of patients with PS =2 in a 
Phase II prospective study (TargeT), in order to determine the efﬁcacy 
and safety of Erlotinib in that population.
Methods: Patient with histologically conﬁrmed stage IIIB or IV 
NSCLC, that were ≥ 18 year old, had adequate bone marrow, he-
patic, and renal function, were pretreated with chemotherapy or were 
untreated patients that were not suitable for ﬁrst line conventional 
chemotherapy were included in the TargeT trial. Patients with poor 
performance status (ECOG = 2) were included in this sub analysis. 
Patients were treated with Erlotinib single agent 150 mg/day p.o. until 
disease progression or withdrawal. Evaluation of the safety proﬁle was 
determined by NCI CTCAE version 3.0.
Results: 386 patients with poor PS and advanced NSCLC were ana-
lyzed in this study. Median age was 67 years (range 28-95), 99% of the 
patients were Caucasian, there was 73.8% males and 26.2% females. 
The stage of the patients was: IIIB/ 18.9% and IV 81.9%. The Histol-
ogy was adenocarcinoma / squamous / large cell / others 54%, 22%, 
18% and 6% respectively. First line patients were 35%, 2nd line 34% 
and 3rd line 31%. Current smokers or patients that have smoked were 
78%. In the population evaluable for response (148 patients), 1 CR, 23 
PR, 57 SD were observed (ORR 16.2%). Clinical beneﬁt (CR+PR+SD) 
was 54.7%. RR is much higher in females (34.8%) than males (8.6%) 
(p<0.0001) and in never smokers (45.7%) than in smokers (7.2%) 
(p<0.0001). Median TTP was 3.33 months (95% CI 2.7 - 5.1). The mul-
tivariate analysis showed that no smoking history correlated with better 
TTP (p<0.0025).Rash was the predominant toxicity occurring in 44.8% 
of the patients and diarrhea was observed in 24%, but only one grade 4 
was reported. 
Conclusions: Erlotinib is safe, well tolerated and active in patients 
with advanced NSCLC and poor performance status. In the multivariate 
analysis, smoking history is the main predictive factor. Further studies 
in this population are warranted.
P3-082 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Erlotinib as third and successive line of treatment in advanced or 
metastatic non-small cell lung cancer patients 
García-Velasco, Adelaida1 Pérez-Carrión, Ramón2 de Castro, Javier3 
Garrido, Pilar4 García, Ramón5 González-Larriba, José-Luis6 Martín, 
Germán7 Provencio, Mariano8 Regueiro, Pilar9 Massutí, Bartomeu10 
1 1Institut Català d’Oncologia. H. Doctor Josep Trueta, Gerona, Spain 
2 MD Anderson International, Spain, Madrid, Madrid, Spain 3 Hospital 
Universitario La Paz, Madrid, Spain 4 Hospital Universitario de La 
Princesa, Madrid, Spain 5 Hospital General Universitario Gregorio 
Marañón, Madrid, Spain 6 Hospital Clínico San Carlos, Madrid, Spain 
7 Hospital Universitario de Salamanca, Salamanca, Spain 8 Hospital 
Universitario Puerta de Hierro, Madrid, Spain 9 Roche Farma, S.A., 
Madrid, Spain 10 Hospital General Universitario de Alicante, Alicante, 
Spain 
Background: Erlotinib is a selective EGFR inhibitor approved for the 
treatments of patients with non-small cell lung cancer (NSCLC) after 
failure of at least one prior chemotherapy. Although third line treatment 
is not often an option for NSCLC due to the decline in the performance 
status and to the aggravation of symptoms, here we present results of 
an analysis of a large subgroup of patients treated in third or more lines 
in a Phase II prospective study (TargeT).
Methods: Patients with IIIB-IV stage, performance status ≤2, adequate 
bone marrow, hepatic and renal functions, that were previously treated 
for advanced or metastastic NSCLC were included in the TargeT study. 
Erlotinib was given at a dose of 150 mg/day until disease progression 
or withdrawal. Results from patients who received at least two previous 
regimen of treatment were analyzed. Evaluation of response rate (ac-
cording to RECIST criteria), time to progression (TTP), survival and 
safety proﬁle was performed.
Results: 503 patients treated in the TargeT study were on third or 
further line of treatment. Median age was 60 years (range 32-84), 99 
% of them were Caucasian. All of them had received two or more 
previous therapies for metastatic disease. 82% of the patients were 
male and 88% were current or former smokers. Performance status 
0/1/2 was 20%/56%/24% respectively. In 43% of the patients tumor 
histology was adenocarcinoma. 293 patients had measurable disease 
and were evaluable for response. 2 CR, 30 PR (ORR 10.9%), 111 SD 
and 150 PD were observed. Rate of clinical beneﬁt (CR+PR+SD) was 
48.8%. RR was much higher in never smokers (36.4%) than in current 
or former smokers (7.4%, p<0.0001) and in women (25%) than in men 
(7.6%, p<0.0002). 
Analyzing the population by intention to treat median time to progres-
sion (TTP) was 3.2 months (95% CI 2.8–C3.7) and median survival 
time 5.6 months (95% CI 4.6–C6.4). The multivariate analysis showed 
that never smoking history was signiﬁcantly correlated with a better 
TTP (p<0.0026) and overall survival (OS) (p<0.0028).
Erlotinib was well tolerated and no unexpected toxicities were ob-
served. Rash and diarrhea were the most frequent adverse events.
